BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Chime Biologics Partners with Panolos Bioscience for Multi-specific Protein Development

Chime Biologics, a leading CDMO that enables biologic therapeutics development announced a strategic cooperation agreement with Panolos Bioscience, a South...

September 25, 2023 | News

MediLink Therapeutics Focuses on Advancing ADCs for Cancer Treatment

On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to ...

September 25, 2023 | News

Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL

"Patients with relapsed or refractory PTCL worldwide face limited treatment options and a poor prognosis. We are pleased with the CDE's decision to grant p...

September 22, 2023 | News

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to disco...

September 22, 2023 | News

Lynk Pharmaceuticals Secures 322 Million RMB in Series C2 Funding

This round of financing was jointly participated by the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund managed by China Grand Prosperi...

September 22, 2023 | News

Asieris Pharmaceuticals' APL-1702 Achieves Key Milestone in Cervical HSIL Treatment Trial

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs fo...

September 21, 2023 | News

WuXi XDC Launches New Commercial Manufacturing Facilities

New commercial facilities offer one-stop manufacturing services for antibody intermediates, bioconjugate drug substance and drug product Do...

September 21, 2023 | News

Everest Medicines Collaborates with Kezar Life Sciences to Develop Zetomipzomib in Greater China and other Asian Markets

"We are glad to form a partnership with Kezar through our cooperation on zetomipzomib, which will add to our existing renal pipeline, and help solidify Eve...

September 21, 2023 | News

China's NMPA Recommends Priority Review for Cefepime-Taniborbactam in UTI Treatment

"Currently, the clinical challenges from multi-drug resistant infections are severe. The recommendation of priority review by CDE for cefepime-taniborbacta...

September 20, 2023 | News

Cytiva expands scientific, digital, and training offering in China

The facility will host training for more than triple the current number of people per year. The upgraded Fast Trak center will support novel therapy dev...

September 18, 2023 | News

Porton Advanced and BRL Medicine Partner to Fast-Track Gene and Cell Therapy Commercialization

BRL Medicine, with its strong gene editing technology, robust R&D capabilities, and prospective pipelines, has been devoted to the realm of CGT for yea...

September 15, 2023 | News

Cure Genetics and Frametact Strike $60M Deal for Familial Neurological Disease Gene Therapy

The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of fa...

September 15, 2023 | News

BioRay's Zuberitamab (Anruixi®) First Domestic Anti-CD20 Antibody Approved in China

In preclinical studies, Anruixi® showed stronger antibody-dependent cell-mediated cytotoxicity (ADCC), a larger volume of distribution at steady state,...

September 14, 2023 | News

MGI Launches the DCS Lab Initiative to Expand Global Omics Access and Capabilities

"We are proud that through the DCS Lab Initiative, MGI technology and innovation will empower researchers and scientists in achieving their next breakthrou...

September 12, 2023 | News

Stay Connected